Actively Recruiting
Noninvasive Intratumor Heterogeneity Evaluation in HNSCC
Led by First Affiliated Hospital of Chongqing Medical University · Updated on 2025-06-18
700
Participants Needed
1
Research Sites
24 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study focuses on tumor heterogeneity, a core challenge in the field of oncology, and innovatively utilizes patient imaging data to deeply mine and analyze intratumoral heterogeneity. By constructing an imaging analysis model for tumor heterogeneity and associating this model with clinical, pathological, transcriptomic, and metabolomic data of patients, a multi-omics decoding of tumor heterogeneity is achieved. The main questions it aims to address are: Can the ITH model stratify patients' treatment efficacy and prognosis assessment? Can pathological and multi-omics sequencing map the mechanisms behind the ITH model?
CONDITIONS
Official Title
Noninvasive Intratumor Heterogeneity Evaluation in HNSCC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathologically confirmed head and neck squamous cell carcinoma (HNSCC)
- Complete clinical, imaging, and pathological data available
- Available complete follow-up information
You will not qualify if you...
- Prior chemotherapy or radiotherapy before surgery
- Poor quality imaging data
- Tumors too small to be easily identified
- History of other concurrent malignant tumors
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Chongqing Medical University
Chongqing, China
Actively Recruiting
Research Team
X
xinwei Chen
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here